Larimar Therapeutics (LRMR) Change in Cash (2013 - 2025)

Larimar Therapeutics (LRMR) has reported Change in Cash for 13 consecutive years, with -$4.7 million the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Change in Cash fell 83.11% year-over-year to -$4.7 million; the trailing twelve-month figure through Dec 2025 stood at $52.2 million (up 809.94% YoY), and the FY2025 full-year result was $52.2 million, up 809.94% from the prior year.
• Change in Cash slipped to -$4.7 million in Q4 2025 per LRMR's latest filing, from $69.6 million in the prior quarter.
• Across five years, Change in Cash topped out at $84.7 million in Q1 2023 and bottomed at -$77.8 million in Q2 2024.
• Historically, Change in Cash has averaged $826550.0 across 5 years, with a median of -$3.7 million in 2024.
• The sharpest annual moves came in 2021 and 2022: Change in Cash tumbled 4781.15% in 2021, then soared 7309.05% in 2022.
• Over 5 years, Change in Cash stood at -$1.4 million in 2021, then slumped by 4047.2% to -$59.2 million in 2022, then jumped by 79.78% to -$12.0 million in 2023, then jumped by 78.43% to -$2.6 million in 2024, then sank by 83.11% to -$4.7 million in 2025.
• According to Business Quant data, Change in Cash over the past three periods registered -$4.7 million, $69.6 million, and -$539000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.